Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Hill Visits Yield Key Bill Support; Plus Medicare, Biosimilar Wins

Angus Worthing, MD, FACP, FACR  |  May 20, 2019

Greetings from Washington, D.C., where ACR leaders just held more than 100 meetings on Capitol Hill supporting reforms to step therapy and prior authorization, increased reimbursement for dual-energy X-ray absorptiometry (DXA), solutions to the rheumatology workforce shortage, and rheumatology-specific research at the Pentagon. We’re already hearing great news about our successes: Hours after our visit, Representatives Schakowski and Burgess introduced a bill to repay medical school loans for pediatric rheumatologists (and other specialists), to help solve a critical need for kids with arthritis. We also generated interest in the Senate to introduce a companion bill to the House’s Safe Step Act, which would allow our patients to be exempted from step therapy in cases where you predict the insurance-preferred drug will be ineffective, cause side effects or reduce adherence—or have another common sense reason.

Keep the momentum going by taking one minute right now to send a pre-written email to Congress. Visit the ACR website (for rheumatologists and rheumatology professionals) or simpletasks.org (patients and families). Your emails will help convince your elected leaders that our initiatives matter. And follow the fun at #Act4Arthritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

RheumPAC
For U.S. based ACR/ARP members, after you send those emails to Congress, do two more quick things: First, decide for yourself what it’s worth to your practice and your patients for the ACR to be fighting for us in Washington, D.C., and make an investment in RheumPAC. Last year, 4% of ACR/ARP members made that calculation about the value of advocacy and supported our bipartisan political action committee (PAC) on behalf of the other 96% of members. Imagine what we would be able to accomplish if that number increased to just 10%—per the ACR’s strategic plan goals.

Second, encourage your medical group, division or state society to support the new RheumPAC Advocacy Fund. What’s that, you say? It’s a fund that allows groups of rheumatologists to support advocacy. While only individuals can give to RheumPAC to support rheumatology champions in Congress, groups can now invest in the Advocacy Fund to defray administrative costs of fundraising, fly-ins and other expenses. Email [email protected] to find out more, or send a check to RheumPAC Advocacy Fund, 2200 Lake Blvd. NE, Atlanta, GA 30319.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A Medicare Win
On May 16, the ACR logged another victory for our patients who receive in-office medications through Medicare. You may remember the ACR strenuously objected last August to the Trump administration’s announcement allowing Medicare Advantage plans to force our patients through step therapy before getting in-office infusion or injection medicines. This week, although the plan remains in effect, Medicare heeded the ACR’s request to protect patients currently receiving therapies (grandfathering/grandmothering) from going through step therapy. Instead of looking back only 108 days to check if patients are currently taking a medicine, plans must look back 365 days, where they will find many of our patients being treated at less frequent intervals.

Page: 1 2 3 | Single Page
Share: 

Filed under:American College of RheumatologyLegislation & AdvocacyMeeting Reports Tagged with:ACR Capitol Hill visitAdvocates for ArthritisBiosimilarsmedical school loansMedicareMedicare Reimbursementpharmacy benefit managers (PBMs)Safe Step Act of 2019 (H.R. 2279)step therapy reform legislation

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences